The INK4a/ARF locus on human chromosome 9p resides at the nexus of two critical cell cycle regulatory pathways, the p53 pathway and the retinoblastoma (pRb) gene pathway. Through the use of shared coding regions and alternative reading frames two distinct proteins are produced: INK4a is a cyclin-dependent kinase inhibitor whereas ARF binds the MDM2 protooncogene and stabilizes p53. We have examined the expression patterns of the INK4a/ARF locus at the RNA level in normal human and murine tissues to determine if these genes are coordinately regulated. We found that both INK4a and ARF were expressed in most tissues at low levels detectable only by RT ± PCR. The pancreas was an exception in that it expressed no detectable ARF mRNA but expressed high levels of INK4a mRNA. Furthermore, human pancreas expressed an additional previously unrecognized splice variant of INK4a, termed p12, through the use of an alternative splice donor site within intron 1. The p12 transcript produced a 12 kD protein composed of INK4a exon 1a and a novel intronderived C-terminus. This novel protein did not interact with cdk4 but was capable of suppressing growth in a pRb-independent manner. The implications of the capacity of the INK4a/ARF locus to encode a third transcript, and for pancreatic cancer, in which the INK4a/ARF locus is nearly always altered, are considered.
Introduction
Regulation of mammalian cell division is a highly complex process involving many dierent pathways and control proteins. Perturbation of one or more of these control mechanisms is a hallmark of almost every form of cancer. The INK4a/ARF locus on chromosome 9 in particular is emerging as a key regulator of two of the most important cell cycle regulatory pathways, the p53 pathway and the retinoblastoma (pRb) gene pathway (Haber, 1997) . The unique aspect of the INK4a/ARF locus is that it encodes two distinct cell cycle regulatory proteins, p16INK4a and ARF (alternative reading frame, murine p19ARF, human p14ARF Stott et al., 1998) , p16b ) through the use of unique ®rst exons (exon 1a for INK4a and exon 1b for ARF). The exons are driven by unique promoter sequences separated by nearly 20 kilobases (kb) which then splice onto common exon 2 and 3 sequences but utilize dierent reading frames to create two totally unrelated proteins from a shared coding region (Mao et al., 1995; Quelle et al., 1995; Stone et al., 1995) .
The INK4 family of proteins (p15INK4b, p16INK4a, p18INK4c, p19INK4d) block cyclin Ddependent kinase (cdk) activities by preventing their association with the D-type cyclins leading to G1 arrest (Ruas and Peters, 1998; Serrano et al., 1993) . Arrest is mediated primarily through hypophosphorylation of pRb, a substrate of the cyclin D/cdk complex. The product of the Rb gene binds to and inhibits the E2F family of transcriptional regulatory proteins, which then act as repressors of E2F target genes. When pRb is phosphorylated in these complexes the E2F proteins are free to transactivate their target genes and their products promote cell cycle progression (Sherr, 1996) . Mutation of INK4a was ®rst demonstrated in familiar melanoma (Hussussian et al., 1994; Kamb et al., 1994) and INK4a remains the only member of the INK4 family shown to act as a tumor suppressor gene in humans. Mutation, deletion, or methylation of INK4a is common in many tumors, with a frequency ranging from approximately 30% in esophageal tumors, to nearly 100% in pancreatic carcinomas (Caldas et al., 1994; Ruas and Peters, 1998; Schutte et al., 1997) .
ARF, the second gene product derived from the INK4a locus, does not bind to cdks nor inhibit the activities of cyclin-cdk complexes, however overexpression of ARF results in cell cycle arrest in both G1 and G2 (Quelle et al., 1995) . Cell cycle arrest mediated by ARF was abolished in cells lacking functional p53, indicating that ARF may act upstream of p53 (Kamijo et al., 1997; Pomerantz et al., 1998; Serrano et al., 1996) . The cell cycle inhibitory activities of ARF are encoded entirely by sequences within the unique exon 1b . The role of ARF in tumorigenesis was ®rmly established in mice using a targeted disruption of exon 1b. ARF-null mice developed lymphomas and sarcomas at an early age (Kamijo et al., 1997) , a phenotype very similar to that of a previous INK4a exon 2 knockout which eectively disrupted both INK4a and ARF (Serrano et al., 1996) .
Two recent studies have shed light on the function of ARF in the p53 pathway. In one study, ARF was shown to bind to and induce the degradation of the MDM2 proto-oncogene, resulting in a stabilization of p53 (Zhang et al., 1998) . MDM2 is known to bind p53 and mask its ability to act as a transcriptional transactivator (Oliner et al., 1992 (Oliner et al., , 1993 . MDM2 binding to p53 also targets it for degradation in the ubiquitin pathway, thus keeping p53 levels low (Haupt et al., 1997; Kubbutat et al., 1997; Levine, 1997) . In a second study, ARF was shown to block MDM2's ability to mask the transcriptional activating function of p53, suppress oncogenic transformation in a p53 dependent manner, and be necessary for the ecient execution of the p53-dependent apoptotic response (Pomerantz et al., 1998) .
We have previously cloned and characterized the promoter region of the human ARF gene (Robertson and Jones, 1998) and were interested in assessing the expression patterns of the INK4a and ARF tandemly linked genes in normal human tissues to determine if there was any form of coordinate regulation. Expression of ARF mRNA in human tissues was ubiquitous with a single exception, the pancreas. Both human and murine pancreatic tissues were ARF mRNA-negative. This absence of ARF mRNA was not due to a lack of appropriate transcription factors in a pancreatic cell line or to CpG methylation of the ARF promoter in normal pancreatic tissue. Human pancreas did however express high levels of INK4a mRNA. Interestingly, a novel and previously unrecognized transcript was detected speci®cally in human pancreas resulting from the use of an alternative 5' splice donor site within the ®rst intron of INK4a giving rise to a longer mRNA transcript. The novel transcript, when translated, produced a truncated INK4a transcript of approximately 12 kiloDaltons (kD) containing exon 1a and a novel C-terminus (p12). Immunoprecipitation studies indicated that p12 did not interact with cdk4, however expression of p12 in tumor cell lines signi®cantly suppressed growth in a pRb-independent manner. Thus an additional level of complexity is imposed on the INK4a/ARF locus, which can encode three distinct transcripts in a tissue-speci®c manner. This ®nding may have important implications for pancreatic cancer, one of the few cancers in which this locus is nearly always targeted for inactivation.
Results

INK4a/ARF expression patterns in normal tissues
We initially sought to determine if the INK4a/ARF tandemly linked genes were coordinately regulated, since their unique organization might allow for the upstream ARF transcript to interfere with initiation of transcription from the downstream INK4a promoter (Figure 1a) . Expression of both transcripts was monitored in cDNA libraries derived from eight dierent normal human tissues by PCR with 5' primers located in the unique exon 1 sequences for each transcript and a common 3' primer located in exon 3, followed by Southern hybridization with ®rst exon-speci®c probes (Figure 2a) . Ampli®cation of the beta-actin transcript was used as a control of sample quality. Results indicated that ARF and INK4a were nearly ubiquitously expressed. ARF mRNA was detectable in all tissues examined except pancreas and skeletal muscle, while INK4a mRNA was detectable in all tissues examined except brain and skeletal muscle. Interestingly in the pancreas, the only tissue expressing INK4a but lacking detectable ARF mRNA, an additional INK4a transcript of larger molecular weight was detected (p12 in Figure 2a , middle panel). Thus the expression patterns from the INK4a/ARF locus in normal tissues were similar to our previous study of ®fteen tumor-derived cell lines (Robertson and Jones, 1998 (Figure 1b) .
Murine tissues were also examined for INK4a and ARF expression patterns (Figure 2b ). ARF-speci®c primers located in exons 1b and 3 showed that ARF mRNA was detectable in all murine tissues examined in a previous study (Quelle et al., 1995) , but was not detected in murine pancreas, which to our knowledge has not been examined previously and was consistent with our results for human pancreas (Figure 2a) . Expression of INK4a (Figure 2b , middle panel), detected with primers in exons 1a and 2, indicated that INK4a was also expressed in all murine tissues, in contrast to a previous study (Quelle et al., 1995) , although the levels in murine pancreas were lower than in most other tissues. The dierence between our study and that of Quelle et al. (1995) may be due to dierences in sensitivity of the PCR. Our primers ampli®ed a much smaller region spanning only intron 1, while the previous study made use of primers spanning the entire INK4a transcript. RT ± PCR with murine tissues also revealed that the alternatively spliced form of INK4a seen in human pancreas was not observed in murine pancreas and thus may not be evolutionarily conserved. Ampli®cation of murine GAPDH, which served as a positive control for RNA integrity, was equal for all RNA samples (Figure 2b , bottom panel).
INK4a and ARF promoter constructs are transcription competent in a pancreatic cell line Given the near universal expression of ARF in normal human tissues (Figure 2a ) and cell lines retaining the locus we wished to determine if the complete lack of ARF trancripts in the pancreas was due to a block in transcription. The previously described ARF (-2465, -331 and -151 relative the transcription start site) and INK4a (-1729, -654, -474 and -293 relative to the 5' most transcription start site) promoter sequences (Robertson and Jones, 1998) were fused to the chloramphenicol acetyltransferase (CAT) gene and transfected into the PANC-1 pancreatic cell line in which the endogenous INK4a/ARF locus has been deleted . The results indicated that both the necessary transcription factors were present for ARF and INK4a promoter activity, and the ARF promoter was slightly more active than the INK4a promoter when the most active constructs were compared (data not shown). We cannot rule out the possibility that the PANC-1 cell line no longer maintains the same complement of transcription factors present in normal pancreatic cells. Our previous work indicated that the ARF promoter can be subject to hypermethylation-mediated transcriptional silencing at low frequency in cell lines (Robertson and Jones, 1998) and while CpG island methylation has not been demonstrated in normal tissues except in the cases of imprinted genes (Efstratiadis, 1994) and X chromosome inactivation in females (Panning and Jaenisch, 1998), we tested for methylation of the CpG island associated with the ARF promoter. Digestion of DNA derived from a normal human pancreas with the methylation sensitive enzymes HpaII, HhaI, SmaI, SacII, SalI, AatII, and NaeI, followed by Southern hybridization with an ARF promoter probe, gave a pattern indicative of complete hypomethylation at all CpG sites examined (data not shown) indicating that lack of ARF mRNA must be due to an alternative regulatory mechanism.
Characterization of the human pancreas-speci®c INK4a splice variant
Normal human pancreas was unique not only because of the complete lack of detectable ARF mRNA but also because an additional higher molecular weight transcript was detected with the INK4a-speci®c PCR primers which also hybridized to an exon 1a-speci®c probe ( Figure 2a ). This transcript was cloned and sequenced and, upon alignment with INK4a genomic sequence (Genbank accession # AC000048), revealed a structure shown schematically in Figure 1b in which an additional 274 bp on intron 1, contiguous with the 3' end of exon 1a, was included in the normal exon 1a sequences followed by the standard INK4a exons 2 and 3. A`GT' splice donor site (Green, 1991) was also found at the end of the novel intron-derived sequences ( Figure 4a ) allowing splicing onto the standard INK4a exon 2 splice acceptor site. The sequence of the novel pancreas-speci®c transcript is aligned with the standard INK4a transcript in Figure 1c and a comparison of the Normal murine tissues were screened by RT ± PCR for expression of ARF (top), INK4a (middle) and GAPDH (bottom) and hybridized in a similar manner with murine-speci®c oligonucleotide probes. Note that the additional band in the ARF rections has been noted previously (Quelle et al., 1995) . Cloning and sequencing of this band revealed that it was unrelated to ARF (not shown). INK4a mRNA, although lower than in other tissues, was detectable in murine pancreas while ARF mRNA was not Figure 3 Northern blot of mRNA derived from normal human tissues. Approximately 2.0 mg of poly-A selected RNA for each tissue (Clontech) was hybridized with, (a) a b-actin cDNA probe, (b) a p12-speci®c oligonucleotide probe derived entirely from intron 1 sequences, and (c) an INK4a exon 3-speci®c oligonucleotide probe. Molecular weights (kb) are indicated at the left and the identity of each transcript is indicated at the right. Note that heart and skeletal muscle are known to express additional actin transcripts human INK4a amino acid sequence with the amino acid sequence predicted from the pancreas-speci®c transcript is shown in Figure 1d . The splice variant, if translated, would encode a peptide of 12.2 kD and we hereafter refer to this transcript as p12. p12 would contain 1.5 of the four ankyrin repeats found in INK4a (Serrano et al., 1993) followed by the intron 1-derived sequence which has no homology to known proteins in Genbank.
INK4a and p12 are expressed at high levels in the pancreas
Screening of human cDNA libraries by PCR indicated which tissues did and did not express the INK4a/ARF transcripts ( Figure 2a ) however these results were semiquantitative and allowed only for con®rmation of those tissues which did not express a given transcript. The relative expression levels of INK4a, ARF, and p12 were therefore assessed by Northern blotting of mRNA isolated independently from the same complement of eight normal human tissues. Probing of the Northern blot with a beta-actin cDNA probe indicated that mRNA was of good quality and equally loaded ( Figure  3a) . Probing the same blot with an oligonucleotide probe speci®c for the p12 alternative transcript (derived entirely from intron 1 sequence) revealed a single band of the expected size for initiation at the known INK4a promoter only in pancreas (Figure 3b ) (Hara et al., 1996; Serrano et al., 1993) . The blot was then stripped and re-probed with an exon 3-speci®c oligonucleotide probe capable of detecting ARF, INK4a, and p12 simultaneously. Figure 3c shows that the same p12 transcript was detected only in pancreas as expected and a second band, corresponding to the size of the standard INK4a transcript (Serrano et al., 1993) , was also detected. An identical hybridization pattern was observed with an exon 1a-speci®c probe (data not shown). It was particularly notable that INK4a mRNA was detectable in normal pancreas as it has been shown in numerous situations that the level of INK4a mRNA is below the detection limit of the standard Northern blot and is only detectable by RT ± PCR methods in normal cells (Alcorta et al., 1996; Khleif et al., 1996; Valle et al., 1997; Yeager et al., 1995; Zindy et al., 1997) , indicating a very high level of INK4a mRNA in the pancreas as compared to other normal tissues. The p12 transcript, while approximately 30% of the intensity of the INK4a transcript, was also detectable.
Comparison of human and murine INK4a intron 1 DNA sequences
The role of the p12 transcript could be to produce a protein of as yet unknown function or p12 could be à dummy' transcript acting to reduce the amount of functional INK4a protein, as was originally assigned to the ARF transcript (Mao et al., 1995) . Conservation at the DNA and particularly the amino acid level across species is often a useful guide in determining if a transcript has an essential function. We thus cloned and sequenced the 5' region of the murine INK4a intron 1 and compared this with the human p12 sequence and the human INK4a genomic sequence available in Genbank (accession # AC000048). Alignment of the human and murine sequences (Figure 4a ) revealed that the exon 1a region was highly conserved as has been noted previously (Quelle et al., 1995) but decreased in the intronic region. Sequence analysis indicated that murine INK4a exon 1a/intron 1 did retain the capacity to code for a peptide of approximately 10 kD (stop codon noted in Figure 4a ). This theoretical 10 kD peptide did not, however, possess signi®cant amino acid similarity to the intron-derived amino acid sequence of human p12 (Figure 4b ) indicating that it has not been well conserved throughout evolution. Several potential`GT' splice donor sites were also detected downstream of the predicted murine stop codon.
The p12 cDNA produces a 12 kD protein immunoreactive with an INK4a antibody and does not interact with cdk4
Our ability to detect p12 protein in normal pancreatic tissue was greatly hindered by the diculty in obtaining suitably preserved normal tissue. We therefore determined if the p12 cDNA could code for the Figure 5a shows that the antibody was speci®c for INK4a expressed from the endogenous locus in C-33A cells (a high level INK4a-expressing cervical cancer cell line (Hara et al., 1996) ), transfected with empty expression vector (pcDNA3.1, right panel) and from an INK4a expression vector transfected into the INK4a-/ARF-pancreatic cell line PANC-1 (p16senseNeo, left panel). PANC-1 and C-33A cells transfected with the p12 expression vector (p12senseNeo) produced a protein of approximately 12 kD reactive with the INK4a antibody. PANC-1 cells transfected with empty expression vector served as a negative control for both proteins. Also notable was that less p12 protein was detected than INK4a protein when driven from the same expression vector promoter and with equal amounts of protein extract loaded in each lane. The p12 mRNA and/or protein may therefore be less stable than the INK4a protein and/ or mRNA in these cells.
Immunoprecipitations were carried out to determine if p12 could interact with cdk4 even though it contained only 1.5 of the four ankyrin repeats found in INK4a. Figure 5b shows that when cdk4 was used as the pulldown antibody and INK4a used to probe the Western blot, INK4a protein was readily detectable in C-33A cells which express both INK4a and cdk4 from the endogenous loci. Detection of INK4a was Figure 6 Growth suppression assay. PANC-1 cells (wild-type pRb , dark bars) and C-33A cells (mutant pRb (Hara et al., 1996) , light bars) were transfected in triplicate with the indicated expression vectors and placed in G418 selective media for 12 days. The number of viable cells was counted and expressed relative to the empty expression vector control (pcDNA3.1, set at 100%). Error bars are the standard deviation from the mean speci®c for the cdk4 pulldown since an irrelevant antibody to the Sp1 transcription factor gave no signal. When C-33A cells were transfected with the p12 expression vector, no 12 kD band was detected in the cdk4 immunoprecipitation even after long exposure. We obtained an identical result using the PANC-1 cell line (data not shown) indicating that there were no additional pancreas-speci®c factors that might mediate the interaction. Our results are also consistent with recent X-ray crystal structure data on the interaction of INK4a with cdk6 which indicated that the second and third ankyrin repeats of INK4a, which are no longer intact in p12, mediate most of the interactions with cdk6 (Russo et al., 1998) .
p12 acts as a growth suppressor
To determine if the protein encoded by the p12 cDNA could in¯uence cell growth and if the pRb status of the cell played a role, a growth suppression assay was used. We transfected the p12 expression vector into the PANC-1 cell line which is deleted for the INK4a/ARF locus but is wild-type for pRb and into the C-33A cell line which retains expression of INK4a but has lost pRb (Hara et al., 1996) , and placed the cells in G418 selection for 12 days after which time the number of viable cells was determined. Figure 6 shows that expression of p12 suppressed growth by nearly 40 and 60% in C-33A and PANC-1 cells, respectively, relative to empty expression vector (pcDNA3.1(+)). Transfection of an INK4a expression vector served as a positive control for growth suppression in PANC-1 cells since they retain pRb. Re-introduction of INK4a will thus restore growth control in these cells and the nearly 80% reduction in cell number was comparable to the results of others (Arap et al., 1997) . Transfection of INK4a into C-33A cells served as a negative control for growth suppression since these cells are mutant for pRb and already express high levels of INK4a. In keeping with this, no signi®cant suppressive eect of INK4a expression was observed with C-33A cells. These results are consistent with the immunoprecipitation studies and indicate that p12 probably does not mediate its eects through the pRb pathway.
Discussion
The present work describes several unique aspects of INK4a and ARF mRNA expression, particularly in normal pancreas. Expression of ARF mRNA was widespread in human and murine tissues. Expression of INK4a was also widespread in humans and mice in contrast to a previous study of murine tissues (Quelle et al., 1995) . Clearly both transcripts were capable of being co-expressed, making it unlikely that transcriptional interference (Proudfoot, 1986; Vales and Darnell, 1989; Wu et al., 1990) was operational unless an as yet unknown mechanism was allowing for allelespeci®c transcription. Human INK4a and ARF expression patterns were unique in the pancreas because: (i) no ARF mRNA was detectable; (ii) INK4a mRNA was present at high levels; and (iii) an alternatively spliced INK4a transcript, termed p12, was detected at high levels. The alternatively spliced transcript was capable of encoding a 12 kD protein immunoreactive with an INK4a antibody whose epitope resides within exon 1a. This novel protein did not interact with cdk4 but was capable of suppressing growth of tumor cell lines in a pRb-independent manner. Lack of ARF expression was conserved in murine pancreas but expression of an additional alternatively spliced form of INK4a was not.
What is the signi®cance of the pancreas-speci®c INK4a/ARF expression pattern? It is unclear why ARF mRNA is absent in the pancreas given its normally ubiquitous expression in tissues and cell lines and its proposed essential function in cell cycle regulation (Kamijo et al., 1997; Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . The absence of ARF mRNA did not result from a lack of the appropriate transcription factors necessary for ARF promoter activity since an ARF-promoter driven reporter gene was active in a pancreatic cell line. Other possibilities include pancreas-speci®c expression of an ARF promoter repressor protein.
If expressed at low levels, the putative repressor may have been titrated out in the transfection experiments since relatively large amounts of plasmid DNA were used. This low level might, however, be sucient to switch o the endogenous gene. An additional possibility is that ARF mRNA is speci®cally destabilized in pancreatic cells. This seems unlikely given that high levels of INK4a mRNA were found and the INK4a and ARF transcripts are identical over nearly 70% of their length. Since pancreatic cells lack ARF it may indicate that the p12 transcript, also expressed exclusively in pancreas, provides some compensatory function. The growth suppression assay supports this notion although it also emphasizes, along with the immunoprecipitations, that this function is unlikely to be mediated through the pRb pathway. It should also be noted that it is unlikely that the eects of p12 are mediated through the p53 pathway since both cell lines used in these studies contain mutant p53 genes (Hollstein et al., 1994) .
What is the potential function of p12? The p12 splicing variant of INK4a, if translated from the endogenous locus in normal pancreas, would contain all of exon 1a and a novel intron 1-encoded Cterminus, but no exon 2 and 3-derived sequences. This transcript can clearly code for a protein with growth suppressive properties but it could also represent à dummy' transcript. The latter might be a mechanism to reduce the amount of functional INK4a protein since p12 protein would contain only 1.5 of INK4a's four ankyrin repeats and it is generally believed that a minimum of two ankyrin repeats are necessary to function as protein ± protein interaction domains (Michaely and Bennett, 1992; Serrano et al., 1993) . The X-ray crystal structure of INK4a interacting with cdk6 also supports this notion since it was found that the second and third ankyrin repeats of INK4a were most important for the interaction with cdk6 (Russo et al., 1998) . What is also fascinating is the parallel between p12 derived from INK4a and p10, an alternatively spliced form of human p15INK4b (Tsubari et al., 1997) . The splicing structure of p10 is identical to that of p12 in that intron 1-derived sequences contiguous with the 3' end of p15INK4b exon 1 are included in the standard transcript and the intron-derived sequence contains an in-frame stop codon. The critical dierence between p12 and p10 is in their expression patterns. p10 appeared to be ubiquitously expressed as analysed in cell lines (Tsubari et al., 1997) , while we have found p12 only in normal human pancreas, although we have not examined all human tissues in this study. INK4a and p15INK4b are highly homologous in their exon 2 regions but much less so in their exon 1 regions thus it was surprising that the capacity to code for an alternatively spliced form was preserved and may therefore be indicative of an essential function maintained through evolution.
The study of p12 was hampered by two factors. The ®rst was the diculty in obtaining suitable preserved normal human pancreas so that Western blotting studies to detect p12 protein could be carried out. Pancreatic tissue is the main producer of many of the nucleic acid and protein degrading enzymes found in the body (Chirgwin et al., 1979; Longnecker, 1982) , requiring that it be obtained and frozen immediately after removal from the patient. Such studies will be performed as tissue becomes available. The second factor was that nearly all pancreatic cell lines studied have sustained deletions of the INK4a/ARF locus . One commercially available cell line which has retained the locus, CFPac-1, was examined for its INK4a/ARF expression pattern. Previous work indicated that this line possessed a hypermethylated, silenced INK4a gene . We con®rmed this observation and found that CFPac-1 also expressed high levels of ARF mRNA by RT ± PCR. Treatment with the demethylating agent 5-aza-CdR resulted in re-expression of INK4a, continued expression of ARF, but no expression of the p12 transcript (data not shown), thus this cell line (INK4a ) and did not serve as a good experimental model.
Another surprising ®nding was that pancreatic tissue expressed a high level of INK4a mRNA. We have not yet determined if this high level of mRNA results in an equally high level of INK4a protein due to the diculty in obtaining suitably preserved tissue. It is interesting to speculate, however, on the potential role of ARF transcription in this ®nding. From this and our previous study (Robertson and Jones, 1998) , it did not appear that transcription of ARF could inhibit the expression of INK4a by transcriptional interference. It was intriguing however that the only case demonstrating an INK4a + /ARF 7 expression pattern expressed a very high level of INK4a mRNA. Studies with exon 1b knockout mice did indeed indicate that INK4a mRNA levels were elevated relative to those in wild-type mice however this was not rigorously quantitated or studied by Northern blotting (Kamijo et al., 1997) . Although we did not detect a similar transcript in murine pancreas we cannot rule out the possibility that the alternatively spliced form of INK4a is expressed in response to certain stimuli not present in our mice, an idea currently under study. Pancreatic tissue has been found to be highly responsive to stimuli from many dierent sources (Iovanna et al., 1991) . Utilization of the p12 splice donor site, and thus the production of p12, could also be regulated by ARF transcription through a form of splice site competition for example (Green, 1991) , since p12 has only been detected when ARF mRNA was undetectable. Further support for this comes from the p10/p15INK4b example mentioned previously in which no`ARF-like' transcript upstream of p15INK4b has been shown to exist and p10 expression is widespread (Tsubari et al., 1997) . It is also possible that the expression of p12 is associated with a non-cancerous disease state, such as diabetes or cystic ®brosis (Longnecker, 1982) .
What is the implication of INK4a/ARF expression patterns for pancreatic cancer? The association between lesions in the INK4a/ARF locus and pancreatic cancer is nearly 100%, the highest of any form of human cancer (Rozenblum et al., 1997; Schutte et al., 1997) . It was very interesting that this was the same tissue which possessed a unique pattern of INK4a/ARF expression. This unique expression pattern could result in a particular chromatin con®guration predisposing the region to deletion, the most common mechanism of inactivation of the INK4a/ARF locus in pancreatic cancer (Caldas et al., 1994; Rozenblum et al., 1997; Schutte et al., 1997) . Furthermore, given the growth suppressive properties of p12 and the lack of ARF expression, the question arises as to which protein is actually the target for deletion during pancreatic cancer progression. The possible roles of p12 and the consequences of the unique INK4a/ARF expression pattern in the pancreas will be the subject of future study.
Materials and methods
Cell lines, tissue culture, and drug treatments
The pancreatic cell lines PANC-1 and CFPac-1, and the cervical cancer cell line C-33A were purchased from the American Type Culture Collection. PANC-1 was maintained in DMEM, CFPac-1 in IMDM, and C-33A in MEM media; all were supplemented with 10% fetal bovine serum (Life Technologies). For 5-aza-2'-deoxycytidine (Sigma) treatment of CFPac-1, cells were diluted to 2610 5 cells/ml, allowed to grow overnight, then freshly prepared drug was added to a ®nal concentration of 1.0 mM and cells were harvested for RNA by standard procedures 72 h later.
Reporter plasmids, transfection, and CAT assays ARF and INK4a promoter-chloramphenicol acetyltransferase (CAT) fusion constructs have been described in detail previously (Robertson and Jones, 1998) . All numbering of CAT constructs is relative to the transcription start site for ARF (Mao et al., 1995) and the 5'-most start site for INK4a (Hara et al., 1996) . Transfection and CAT assays were performed essentially as described (Robertson and Jones, 1998) . Brie¯y, 6610 5 cells were transfected with 8 ml of lipofectamine reagent (Life Technologies), 2.0 mg of reporter plasmid, and 250 ng of pSV40LacZ for 7 h, after which time serum-containing media was added and the cells were incubated for a total of 48 h before being harvested for cell extract and CAT and beta-galactosidase assays by standard methods (Robertson et al., 1995) . All CAT assays were performed in duplicate and were quantitated on a Molecular Dynamics Phosphorimager. CAT activities were normalized to beta-galactosidase activity to account for dierences in transfection eciency.
Reverse transcriptase (RT) ± PCR
RT ± PCR on cell line RNA was performed as described previously (Robertson and Jones, 1998) . cDNA libraries derived from normal human tissues were purchased from Clontech (Quick-Screen Human cDNA panel). Speci®cally, the pancreatic RNA used for creation of the cDNA was derived from a pool of six male and female Caucasians, ages 27 ± 69, who died of trauma (Clontech). PCR for INK4a and ARF was performed with ®rst exon-speci®c 5' primers 5'-AAC GCA CCG AAT AGT TAC G-3' (for exon 1a) and 5'-CAT GGT GCG CAG GTT CTT G-3' (for exon 1b), and a common 3' primer 5'-TTC CCG AGG TTT CTC AGA G-3' located in exon 3. PCR conditions, probe labeling, and Southern blotting of the PCR products with an exon 1a speci®c probe (5'-CGG TCG GAG GCC GAT CCA G-3') or an exon 1b speci®c probe (5'-TAC TGA GGA GCC AGC GTC TAG-3') were as described (Robertson and Jones, 1998) . Ampli®cation of beta-actin was used as a control for RNA integrity as described previously (Robertson and Jones, 1998) .
Murine tissues were isolated and immediately frozen in liquid nitrogen. RNA was prepared by pulverizing tissue in liquid nitrogen, thawing in Trizol (Life Technologies), then proceeding with the protocol recommended by the manufacturer. For RT reactions, 2.5 mg of RNA was used with random hexamers (Pharmacia) and Superscript II reverse transcriptase (Life Technologies) essentially as described (Gonzalgo et al., 1998) . PCR for murine INK4a, ARF, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was carried out under the following conditions: 948C 2 min, one cycle; 948C 30 s, 588C for 1 min, and 728C for 1 min for 35 cycles (30 cycles for GAPDH), then 728C for 10 min, one cycle. Primer sequences were (sense) 5'-GCT GCA GAC AGA CTG GCC AG-3' for INK4a exon 1a, (antisense) 5'-GTC CTC GCA GTT CGA ATC TGC AC-3' for INK4a/ ARF exon 2, (sense) 5'-TCT TGG TCA CTG TGA GGA TTC-3' for ARF exon 1b, (antisense) 5'-CGG ATT TAG CTC TGC TCT TGG G-3' for INK4a/ARF exon 3, (sense) 5'-CAG CCT CGT CCC GTA GAC AAA ATG G-3' and (antisense) 5'-TTC TGG GTG GCA GTG ATG GCA TGG A-3' for the GAPDH control of RNA integrity. Sequences of oligonucleotide probes were 5'-GGC ACT GCT GGA AGC CGG GGT TTC GCC CAA-3' for INK4a, 5'-TTG AGG CTA GAG AGG ATC TTG AGA AGA GGG-3' for ARF, and 5'-CGG TGC TGA GTA TGT CGT GG-3' for GAPDH.
Cloning human p12 and murine INK4a intron 1
The p12 alternative splice variant of human INK4a was cloned by isolating the desired band from the agarose gel with the Qiaex II gel extraction kit (Qiagen) followed by cloning into the T7-Blue blunt cloning vector (Novagen) to create pKR86-3, followed by sequencing. The p12 sequence is available under Genbank accession # AF115544. The sequence of the standard INK4a PCR ampli®cation product was also con®rmed in a similar manner.
The murine INK4a intron 1 was cloned by PCR using the expand Long Template PCR system (Boehringer Mannheim) with exon-derived primers spanning intron 1. Mouse liver DNA was used as template (250 ng) with reaction buer 3 according to the manufacturer's instructions. PCR conditions were: 948C 3.5 min for one cycle, 948C 15 s, 628C 30 s, 688C 4 min for ten cycles, 948C 15 s, 628C 30 s, 688C 4 min for 20 cycles with an auto-extension time of 20 s/cycle during the extension phase, followed by one cycle of 688C for 7 min. Primers used for PCR were (sense, exon 1a) 5'-CGA TCG AAT TCG CTG CAG ACA GAC TGG CCA G-3' and (antisense, exon 2) 5'-GTC CTC GCA GTT CGA ATC TGC AC-3'. The approximately 4.8 kb fragment generated was then restriction mapped. A SpeI site approximately 1.6 kb from the 5' end (the exon 1a end) was used, along with the EcoRI site incorporated into the 5' PCR primer to subclone the intron into the EcoRI and SpeI sites of pBSKSII (Stratagene) for sequencing. Approximately 600 bp of the 5'-end of the intron was sequenced (not all is shown in Figure  4a ) and is available under Genbank accession # AF115545. All sequencing was performed at the USC DNA Sequencing Core Facility.
Southern and Northern blotting
Methylation Southern blotting of the ARF promoter was performed exactly as described (Robertson and Jones, 1998) on DNA from a normal pancreas obtained at the USC/ Norris Hospital following surgery for duodenal cancer. For Northern blotting, 2.0 mg of mRNA from each of the normal human tissues was size fractionated on a 1.2% formaldehyde agarose gel and transferred to nylon membrane (Clontech). The pancreatic mRNA used for the Northern blot was prepared independently of that used for the tissue PCR screen and was derived from a pool of ten male and female Caucasians, ages 40 ± 61, who died of trauma (Clontech). All oligonucleotide probes were synthesized at the USC Core Facility and labeled with T4 kinase (NEB) to high speci®c activity and unincorporated nucleotides were removed with a Sephadex G-25 column. Hybridization was carried out in ExpressHyb hybridization buer at 488C according to the manufacturer's instructions (Clontech). Probe sequences are as follows: p12-speci®c probe 5'-TCT GTG ATT ACA AAC CCC TTC TGA AAA CTC CCC AG-3', INK4a exon 3 5'-TTC CCG AGG TTT CTC AGA GCC TCT CTG GTT C-3', and INK4a exon 1a 5'-GTA ACT ATT CGG TGC GTT GGG CAG CGC CCC C-3'. The beta-actin cDNA probe was provided by Clontech.
Expression vectors
The INK4a expression vector was created by PCR with primers (sense) 5'-GAT CGA ATT CGC GGG GAG CAG CAT GGA GCC GGC GGC GGG GAG CAG CAT GGA GCC TTC GGC TG-3' and (antisense) 5'-GAT CTG AAT TCT CCC GAG GTT TCT CAG AGC CTC-3' and the plasmid p16-pBSKSII (provided by Dr David Beach) as template (50 ng) with Pfu DNA polymerase (Stratagene) using cycling conditions that have been described previously (Robertson and Jones, 1998) . This PCR product was digested with EcoRI (incorporated into the PCR primers), cloned into the pSG5 (Stratagene) mammalian expression vector to create p16sense, and sequenced. The p12 expression vector was created by PCR with primers (sense) 5'-GAT CGA ATT CGC GGG GAG CAG CAT GGA GCC-3', and (antisense) 5'-GAT CTG AAT TCT CCC GAG GTT TCT CAG AGC CTC-3' and plasmid pKR91-1 (50 ng) as template exactly as described for the INK4a expression vector, to create p12sense. Sequences of all PCR products were con®rmed. The template pKR91-1 plasmid contained the full-length p12 cDNA but lacked the¯anking EcoRI sites. To allow for neomycin (Neo) selection of transfected cells, both the INK4a and p12 cDNAs were moved into the Neo-selectable expression vector pcDNA3.1(+) (Invitrogen). The p16sense and p12sense vectors were digested with EcoRI and the liberated cDNA fragments were cloned into the EcoRI site of pcDNA3.1(+) and screened for orientation to create p16senseNeo and p12senseNeo respectively.
Western blotting and immunoprecipitation
Immunoprecipitation Western blotting was carried out on equal numbers of transfected or mock transfected cells (C-33A (ARF + /INK4a + ) and PANC-1 (ARF 7 /INK4a 7 )) as described above. Forty-eight hours later cells were lysed in cold RIPA buer (Sambrook et al., 1989 ) containing protease inhibitors (1.0 mg/ml aprotinin, 1.0 mg/ml leupeptin, 1.0 mg/ ml pepstatin A, and 0.5 mM PMSF (Boehringer Mannheim)). Cell lysates were vortexed to shear DNA and precleared with normal IgG (Santa Cruz) derived from the same species as the pulldown antibody. Approximately 1.2 ml of precleared lysate was incubated with pulldown antibody (INK4a, N-20, Santa Cruz, USA) and protein A-sepharose beads (Sigma) or antibody-agarose conjugate (cdk4, H-22-AC, or Sp1, PEP-2-G, Santa Cruz, USA) overnight at +48C. Beads were washed, resuspended in 1X SDS-sample buer, and boiled. Protein was loaded onto a 10 ± 20% gradient tris-glycine SDS mini-gel, run according to the manufacturer's instructions (BioRad), transferred to PVDF membrane (MSI), and blocked overnight in 5% BSA/1% dry milk in tris-buered saline (TBS), pH 8.0. Rabbit anti-INK4a 18 antibody (N-20, Santa Cruz, USA) was used at a dilution of 1 : 100 and goat anti-cdk4 antibody (H-22-G, Santa Cruz, USA) was used at a 1 : 200 dilution in antibody incubation buer (1% BSA, 0.05% Tween 20 in 16TBS, pH 8.0). HRP-conjugated secondary antibodies (Santa Cruz, USA) were used at a 1 : 2000 dilution. Chemiluminescent detection was performed with the ECL Detection Kit (Amersham) according to the manufacturer's instructions.
Growth suppression assay C-33A and PANC-1 cells (4610 5 ) were transfected as described above with empty expression vector (pcDNA3.1(+)), p16senseNeo, or p12senseNeo in triplicate in 6-well dishes. Forty-eight hours later, each well was trypsinized and replated into two 100 mm dishes in medium containing 800 mg/ml G418 (Life Technologies). Cells were grown for 12 days then viable cells were counted. No untransfected cells remained viable under these selection conditions.
